Welcome to WindMIL

A platform for cell-based immuno-oncology therapy


ABOUT
WHAT WINDMIL THERAPEUTICS® DOES



At WindMIL, we are harnessing the power of bone marrow derived lymphocytes to develop ground-breaking immunotherapies to treat cancer patients. We have perfected an efficient and rapid process to extract, activate and expand bone marrow derived T cells. The result of this process is called Marrow Infiltrating Lymphocytes or MILsTM. Owing to their derivation from the bone marrow, which is a natural reservoir for memory T cells, MILsTM have unique properties that make them well suited for application in autologous cell therapy. Our lead program is in a Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILsTM advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.


TECHNOLOGY
WHAT MAKES MILS SPECIAL




MILsTM represent a novel class of cell therapy. While the vast majority of cell therapy approaches rely on lymphocytes derived from the periphery, MILsTM are derived from the bone marrow. This is important, because, put simply, in cell therapy…cell source matters. The bone marrow is a natural reservoir for memory T cells. WindMIL’s founders were among the first to describe the presence of tumor-specific memory T cells in the marrow of cancer patients. Producing MILsTM from this cell source results in a cell therapy product with several unique features including:

• Inherent tumor specificity
• Maximal cytotoxicity due to memory phenotype
• Long persistence


PIPELINE
WHAT WINDMIL IS WORKING ON




Unmodified MILs

The specificity inherent in the native TCRs of the T cells that form MILsTM eliminates the need for genetic modification entirely. This freedom has proven both to lower manufacturing cost and lower toxicity. It also eliminates the need to pre-identify a tumor-specific antigen, something that has proven difficult in solid tumors in particular.

Unmodified MILs are currently being studied in a randomized, multi-center, Phase II trial in high risk multiple myeloma. WindMiL also plans to open additional trials in solid tumors in the near future.

MIL CARs

Bone-marrow derived memory T cells are known to be the body’s most effective generators of a cytotoxic response and are highly persistent. These two features make MILsTM the ideal cell source from which to create CAR-T cells. Furthermore, the native TCR of MILsTM should allow recognition of the tumor even if the cognate antigen of the CAR is no longer expressed by the tumor.

MIL CARs are currently in preclinical development.

genMILs

WindMIL is also investigating a variety of proprietary genetic modifications to MILsTM. For instance, we believe certain proprietary genetic modifications may make MILsTM capable of functioning in highly suppressive tumor microenvironments.

genMILs are currently in preclinical development.
MEET OUR TEAM
THE EXPERTS THAT DRIVE WINDMIL



  • Management
  • /
  • Board of Directors
  • /
  • Scientific Advisory Board
Brian Halak, PhD
President and CEO

Brian Halak, PhD, partnered with founders Ivan Borrello, MD, and Kimberly Noonan, PhD, to create WindMIL and serves as its founding CEO.

Kimberly Noonan, PhD
Founder and CSO

Kimberly Noonan, PhD, is a scientific cofounder of WindMIL and a pioneer in the use of MILs.

Janice Phillips, PhD
HEAD, TECHNICAL OPERATIONS

Janice Phillips, PhD, has spent her distinguished career involved in the manufacturing of biologics including autologous cell-based therapies.

Monil Shah, PharmD, MBA
Chief Development Officer

Monil Shah, PharmD, is an Oncology Clinical Development leader with previous experience from various large and small pharmaceutical companies.

Gregory Lumpkin
VP, Finance

Gregory Lumpkin is the founder of GML & Associates, a firm that provides financial and accounting services for emerging companies.

Patrick Dougherty
VP, Operations

Patrick Dougherty is the VP Operations for WindMIL Therapeutics. Prior to joining WindMIL, Patrick was Chief of Staff to the SVP R&D Pipeline for Pharmaceuticals R&D at GlaxoSmithKline (GSK).

Brian Dovey

Brian Dovey has been a partner of Domain Associates since 1988, where he has led investments, and he has served on the board of directors of more than 35 private and public companies.

Allan Fox

Allan Fox is the founding partner of FOXKISER, a nationally recognized firm specializing in biomedical research and development, law and public policy.

Howard Soule, PhD

Howard Soule, PhD, is a senior fellow, executive vice president, and chief science officer of the Prostate Cancer Foundation.

Mark McDade

Mark McDade spent over 20 years as the CEO or COO of multiple successful biotech companies before helping to establish QiMing US.

Anna French, PhD

Anna French, Ph.D., was a strategic consultant to BioPharm and a well published scientist focused on stem cell research before joining QiMing US.

Don Hayden

Don Hayden had a highly successful 25-year career with Bristol-Myers Squibb Company where his most recent role was President, Global Pharmaceuticals.

Brian Halak, PhD
CEO

Brian Halak, PhD, partnered with founders Ivan Borrello, MD, and Kimberly Noonan, PhD, to create WindMIL and serves as its founding CEO.

Kenneth Anderson, MD

Kenneth Anderson, MD, is widely recognized as a leading expert in the field of multiple myeloma.

Ivan Borrello, MD
Founder and Senior Clinical Advisor

Ivan Borrello, MD, is a scientific cofounder of WindMIL and a pioneer in the use of MILs.

Marcela V. Maus, MD, PhD

Marcela V. Maus, MD, PhD, is a pioneer in the area of adoptive cell therapy. 

Drew Pardoll, MD, PhD

Drew Pardoll, MD, PhD, is an internationally recognized authority in cancer immunology and immunotherapy. 

Howard Soule, PhD

Howard Soule, PhD, is a senior fellow, executive vice president, and chief science officer of the Prostate Cancer Foundation.

Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD, is widely recognized for his expertise in human immunology and immune therapies for solid tumors.

CONTACT
REACH OUT TO WINDMIL


1812 Ashland Avenue, 1st Floor, Suite 100, Baltimore, MD 21205
410-558-1906